Kornimate/medical-research-clean huggingface dataset:
horse assisted rehabilitation postoncologic treatment in children and adolescents: physical and psychological effects

Conditions: Cancer; Child, Only; Child Behavior; Neurologic Gait Disorder; Neurologic Complication

Summary: clinical trial on the physical and psychological effects of horse assisted rehabilitation after the treatment of cancer in children 4 to 18 years of age.

randomized controlled open labelled trial. duration: 6 months. groups: control group (standard follow-up) and intervention group (one weekly rehabilitation session assisted by horse). participants: 30 children, 4 to 18 years of age, after 6 months of the discharge of the cancer treatment with nervous system involvement.

Eligibility criteria:
inclusion criteria: * children between 4 and 18 years of age, who had suffered a cancer with affectation of the central nervous system * with or without motor, functional and / or cognitive deficits or neurological disorders due to their basic problem or be as a consequence of the therapeutic procedures, with any degree of disability * more than 6 months after receiving the discharge of oncology (chemotherapy or radiotherapy) exclusion criteria: * immunodepression * hypotonia with severe pelvic instability that does not allow seating on the horse safely * weight greater than 80kg. * phobia to horses

Keywords: child behavior neurologic gait disorder cancer physical therapy modalities physical therapy specialty physical and rehabilitation medicine rehabilitation
the influence of mitraclip on apnoea asleep

Conditions: Sleep Apnoea

Summary: the aim of the present study is to influence the central and obstructive sleep apnoea in patients with severe mitral insufficiency by an interventional mitraclip examination to evaluate.


Eligibility criteria:
inclusion criteria: * patient suffer on severe symptomatical mitral insufficience * male and female patients is planned an interventional mitraclip examination * dyspnea with a nyha (new york heart association) ii - iii * an high logistic euro-score (\> 20) * no execution of surgical intervention because of relevant comorbidities exclusion criteria: * younger than 18 years * pregnancy and breast-feeding * persons without mental ability of capacity to understand and follow the instructions of the investigator * persons in dependence from the sponsor or working with the sponsor * participation in other studies
behavioral activation for perinatal depression

Conditions: Depression During Pregnancy

Summary: this pilot study will examine the feasibility, acceptability, and effectiveness of a brief behavioral activation psychotherapy for women with perinatal depression.


Eligibility criteria:
inclusion criteria: - pregnant phq9 depression score of 15 or greater receiving prenatal care at one of the participating sites exclusion criteria: - known diagnosis of bipolar or psychotic disorder active substance dependence immediate risk of self harm immediate need for inpatient mental health treatment

Keywords: depression pregnancy
self-management in chronic obstructive pulmonary disease (copd) patients compared to usual care

Conditions: Chronic Obstructive Pulmonary Disease

Summary: evaluation of the effectiveness of copd self-management interventions compared to usual on quality of life, functional status, patient education, depression, and anxiety in primary healthcare users in the prefecture of heraklion, greece.

to the best of our knowledge, no previous study has examined the effects of self-management programs on patients with copd in greece. therefore, the investigators conducted a randomized controlled trial with a post-test design, to evaluate the implementation and clinical effectiveness of a copd self-management intervention compared to usual care in terms of the following outcomes: quality of life, functional status, patient education, depression, and anxiety.

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years * had previously been given a physician-diagnosis of mild copd * stable on their medications (no treatment modifications) in the last three months * able to speak, read and/or understand greek exclusion criteria: * refusal to participate * concurrent oncological diseases * severe cognitive impairment * neurological, or psychiatric disability
psychosocial and economic impacts of narrative exposure therapy for violence survivors in eastern drc

Conditions: Mental Health Disorder; PTSD; Depression Anxiety Disorder; Gender-based Violence

Summary: the objective of the study is to evaluate the impact of narrative exposure therapy (net) delivered by local counselors, on the mental health and socio-economic empowerment of survivors of sexual and gender based violence (sgbv) who suffer post-traumatic stress disorder (ptsd), in north and south kivu in eastern drc. the counselors will be trained and supervised by clinical experts from the ngo vivo international. the therapy is expected to reduce the symptoms of ptsd, depression, and anxiety in sgbv survivors. the project is expected to directly impact and improve the beneficiaries' mental health outcomes of interest, and to indirectly impact and enhance their economic empowerment in the medium term and social functioning both in the short and medium term. this proposed impact evaluation will answer the following research questions: 1) what is the impact of net on survivors' psychosocial wellbeing, economic empowerment and social functioning and participation? 2) does the impact of net differ depending on individual and household characteristics as well as context-specific factors?


Eligibility criteria:
inclusion criteria: * gbv survivors who are screened for commonly found conditions of mental distress exclusion criteria: * more severe cases of mental disorders are ineligible. they are referred to the general referral hospitals or specialized mental health clinics to receive immediate treatment.
isoperistaltic versus antiperistaltic anastomosis after laparoscopic right colectomy for cancer

Conditions: Primary Malignant Neoplasm of Ascending Colon

Summary: the study will provide a precise control compared to the two interventions (iso vs antiperistaltic anastomoses) with thorough measurements of the postoperative variables and complications to improve the evaluation of the surgical technique. it will also enable an evaluation of the quality of life after the procedures.


Eligibility criteria:
inclusion criteria: * the patient has given informed consent to participate * no surgery contraindications * elective surgery * no pregnancy or nursery during the study * older than 18 years * complete preoperative cancer staging * tumour characteristics: * cecum, ascending, hepatic angle or transverse colon tumour confirmed by endoscopic biopsy * radiologically resectable tumours * absence of vascular, nervous or bone infiltration * t4 stages with near organ infiltration * absence of peritoneal carcinomatosis * absence of respiratory pathology that prevents for doing hydrogen breath test exclusion criteria: * pregnancy * intestinal bowel disease like crohn's disease or ulcerative colitis. * metastatic bone illness * previous abdominal surgery with bowel resection * malabsorption syndromes

Keywords: right hemicolectomy side-to-side anastomosis orocecal time antipersitaltic isoperistaltic laparoscopic colectomy right laparoscopic hemicolectomy
the role of therapy for muscle tension dysphagia

Conditions: Muscle Tension Dysphagia

Summary: muscle tension dysphagia is a novel diagnostic taxonomy describing a subset of patient population with reported dysphagia who exhibit normal oropharyngeal and esophageal swallowing function as evidenced by videofluoroscopic swallow study. these patients also demonstrate abnormal supraglottic muscle tension during laryngoscopy as well as signs of laryngeal hypersensitivity and laryngopharyngeal reflux. treatment of these patients with proton pump inhibitor (ppi) therapy is a common practice however voice therapy invention targeting the unloading of the supraglottic muscle tension has been shown to be highly effective in symptom resolution per the investigators' clinical experience. the study is designed to answer efficacy of treatment being offered to patients with muscle tension dysphagia.


Eligibility criteria:
inclusion criteria * age 18-99 * diagnosed with muscle tension dysphagia exclusion criteria * physical or emotional disorder preventing the completion of therapy
cannabis vs opioids pain management objective testing comparisons

Conditions: Chronic Pain; Circulatory Disorders

Summary: our purpose for the study is to find safer, less intrusive, better preforming non-addictive products, as an alternative therapy for pain relief and to help alleviate the opioid epidemic ongoing in america today.

the aasem nationally sponsored/ physicians clinical trial policy ctp (medicare study) testing results will be concluded by the principal investigators (mds and dos) of the study at each site authorized to participate by the aasem, within the highest of scientific mathematical standards, using pain dx neural scan and/or axon ii testing systems, which include amplitude testing certified with promethius potentiometers, for small pain fiber (spf) nerve conduction testing, cms carrier cpt codes 95904 now 95909 through 95913 units, as needed. it is expected that, at a later date, other products used for therapy and/or rehabilitation purposes will be added to the comparison protocol for the national trial number (nct# tba) assigned by the national library of medicine (nlm). other products and/or dme equipment may include: infrared light therapy cpt code 97026, tens therapy and home units cpt therapy code # 97032, as well as montmorillonite minerals for physical applications (montmorillonite is a natural mineral and has no cpt code - is not a cms ordinarily payable event).

Eligibility criteria:
inclusion criteria: * in the investigator's judgment a high probability of 5 year survival. * patient is able to comply with the study visit schedule. * patient has the ability to comprehend and sign an informed consent document prior to study enrollment. exclusion criteria: * in the investigator's judgment not a high probability of 5 year survival. * patient is unable to comply with the study visit schedule. * patient does not have the ability to comprehend and sign an informed consent document prior to study enrollment.
impact on quality of life, fatigue and cognitive function in anti-angiogenesis in patients with metastatic kidney cancer

Conditions: Metastatic Kidney Cancer

Summary: longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer


Eligibility criteria:
inclusion criteria: * patient (e) age (e) over 18 years * kidney cancer metastatic or locally advanced * anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together * proposed treatment in first line or second line * brain imaging not finding brain metastases * having signed the informed consent of study participation * the patient may have received prior anti-angiogenic exclusion criteria: * cancer of the kidney other than primitive * previous history of cancer other than kidney cancer in complete remission for less than 5 years * patients under 18 years * patients whose treatment is associated with chemotherapy * disorders of cognitive functions to existing treatment delivery * pathology psychiatric evolutionary * refusal of participation * patient unable to respond to cognitive tests * drug use * heavy drinking (who criteria) * history of stroke * history of head trauma * brain metastases known * mms below normal compared to existing standards for age and socio-cultural

Keywords: quality of life cognitive functions antiangiogenic agents kidney cancer metastatic
hypofractionated versus conventional fractionation radiotherapy

Conditions: Breast Cancer; Radiation Toxicity

Summary: this study was designed to evaluate the acute toxicity and quality of life of hypofractionated radiation versus conventional when regional node irradiation is indicated after breast-conserving surgery or mastectomy.

investigators hypothesize that hypofractionated radiotherapy is equal effective and safe as conventional radiotherapy in breast cancer patients undergoing regional nodal irradiation. eligible breast cancer patients are randomized 1:1 into the following two groups: 1. hypofractionated therapy: 40 gy in 15 fractions of 2.67 gy in breast or chest wall and nodal drainage with concurrent boost 48.0 gy / 3.2 gy daily in tumor bed, in case of conservative surgery; 2. standard fractionation: 50 gy in 25 fractions in breast or chest wall and nodal drainage with sequential tumor bed boost with 10 gy in 5 fractions in tumor bed in case of conservative surgery. patients will be followed for 6 months after radiotherapy to evaluate acute toxicity and quality of life.

Eligibility criteria:
inclusion criteria: * female; * older than 18; * breast cancer stage t1 - t3; * at least 1 lymph node positive; * treated with mastectomy or conservative surgery; * negative surgical margins; * no distant metastasis; * no supraclavicular or internal mammary nodes metastases; * adjuvant systemic therapy with chemotherapy, endocrine therapy or anti-her2 (human - - epidermal growth factor receptor 2) treatment is accepted; * signed informed consent. exclusion criteria: * positive surgical margins; * concomitant chemotherapy; * supraclavicular or internal mammary nodes metastases; * distant metastasis; * previous thoracic radiotherapy; * bilateral breast cancer; * patients with collagen diseases; * unable or unwilling to sign inform consent.

Keywords: breast cancer radiotherapy hypofractionated therapy nodal irradiation
study to assess the safety and tolerability of incremental doses of qab149 in adults with mild-to-moderate chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: the purpose of this study is to determine the safety and tolerability of single doses of qab149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate copd.


Eligibility criteria:
inclusion criteria: * male and/or female patients with mild to moderate stable copd, diagnosed according to the global initiative for chronic obstructive lung disease (gold) guidelines; 40-75 years of age * prebronchodilator baseline forced expiratory volume in 1 second (fev1) 30-80% of the quanjer predicted normal value (quanjer et al. 1993) and at least 0.75 l with fev1/forced vital capacity (fvc) \< 70% of predicted \[gold guidelines\]. * previous smokers (\>10 pack-years). ten pack years are defined as: 20 cigarettes a day for 10 years; 10 cigarettes a day for 20 years; or 40 cigarettes a day for 5 years. current smokers, with \>10 pack year history, can be included under certain conditions. * vital signs (after 3 minutes resting measured in the supine position) which are within the following ranges: * oral body temperature between 35.0-37.5 °c; * systolic blood pressure, 100-170 mm hg; * diastolic blood pressure, 50-100 mm hg; * pulse rate, 50 - 90 beats per minute (bpm). * patients must weigh a minimum of 50 kg to participate in this study. * able to provide written informed consent prior to study participation. * able to communicate well with the investigator and comply with the requirements of the study. exclusion criteria: * pregnant women or nursing mothers. * patients with a qtc interval above 0.43 seconds for males and 0.45 seconds for females at the screening visit. if pre-treatment values on day 1 of the treatment periods exceed 0.45 and 0.47 seconds for males and females respectively the visit may be re-scheduled once. * patients with a history of prolonged qtc intervals, or a family history of prolonged qt syndrome. * predominant diagnosis of asthma. (patients must present without evidence of active asthma.) * patients who have been hospitalized or had emergency treatment for acute copd exacerbation in the one month prior to or during screening. * patients who have had a respiratory tract infection within one month prior to screening. * patients with concomitant pulmonary disease, including a history of cancer other exclusion criteria apply.

Keywords: copd, indacaterol, pk
effect of wholegrain wheat on body weight and composition and cardiovascular risk

Conditions: Obesity

Summary: the aim of this study is to investigate the potential beneficial effect of wholegrain on body weight and composition as well as cardiovascular risk in overweight women.

objective: to study the effect of the 'wholegrain concept', i.e. high intake of wheat wholegrain (ww) vs. refined wheat (rw) grain products on body weight and composition. design: in this open-labeled randomized trial, 72 postmenopausal women with metabolic syndrome features were prescribed a mild calorie-restricted diet with a deficit of \~1,250kj/d. following 2 weeks run-in period on rw products, they were randomized to 12 weeks intervention with rw or ww products providing 2,000kj/d.

Eligibility criteria:
inclusion criteria: * bmi 27-37 * postmenopausal (\>1y) women * 40-70 years old exclusion criteria: * medication (hypertensive treatment not included) * bp \> 160/100 * fasting glucose \> 7mm * fasting cholesterol \> 6.5mm * smoking * known chronic illnesses

Keywords: obesity wholegrain wheat cardiovascular disease
topical diclofenac on macular thickness after phacoemulsification

Conditions: Diabetic Oculopathy

Summary: eyes of 108 diabetic patients have underwent phacoemulsification and intraocular lens implantation surgery have enrolled. fifty four eyes have received the conventional postoperative care with steroid drop, whereas the other group (54 eyes) have given a preoperative diclofenac drop four times daily in addition to steroid drop and continued six weeks after surgery. all patients have evaluated by optical coherence tomography (oct) preoperatively and days 1, 30, and 90.the outcome measures including best corrected visual acuity (bcva) and oct findings were compared in and between both groups.


Eligibility criteria:
inclusion criteria: * diabetic patients with non-proliferative diabetic retinopathy that were candidate for phacoemulsification and intraocular lens implantation exclusion criteria: * eyes with clinically significant macular edema based on the etdrs(early treatment diabetic retinopathy study) study and/or central macular thickness \>260µ were not included. neither did we include the eyes with other accompanying diseases affecting the macula or eyes with history of previous retinal laser photocoagulation or intraocular surgery. * eyes with severe cataract that preclude performing an acceptable quality optical coherence tomography (oct) were not enrolled either.

Keywords: diclofenac macular thickness phacoemulsification oct(optical coherence tomography ) diabetic
study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of jnj-64565111 in type 2 diabetes mellitus (t2dm)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to assess the safety and tolerability of jnj-64565111 in adult men and women (of non-child bearing potential) with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus (t2dm) at least 3 months prior to screening * on a stable treatment regimen at least 3 months prior to screening of (1) diet and exercise, or (2) metformin monotherapy (at a dose of at least 1,000 milligram (mg) per day) * blood pressure between 90 and 140 millimeter of mercury (mmhg) systolic, inclusive, and between 60 and 100 mmhg diastolic, inclusive at screening (sitting) and day -2 (supine). if blood pressure is out of range, up to 2 repeated assessments are permitted * hba1c greater than or equal to 6.5% and less than 8.5% at screening * females of non-childbearing potential exclusion criteria: * history of, or currently active, significant illness or medical disorders, including cardiovascular disease (including cardiac arrhythmias, myocardial infarction, stroke, peripheral vascular disease), hematological disease (example, von willebrand's disease or other bleeding disorders), respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmologic disorders, neoplastic disease, skin disorder, renal disorder, or any other illness that the principal investigator (pi) considers should exclude the participant or that could interfere with the interpretation of the study results * previous surgical treatment for obesity (example, gastric bypass, gastric banding) * history of diabetic neuropathy with signs of gastroparesis and/or known proliferative retinopathy or maculopathy * history or current diagnosis of acute or chronic pancreatitis * history of an invasive cardiovascular surgical procedure including, but not limited to, coronary artery bypass graft (cabg), or percutaneous coronary intervention (pci)
high-flow nasal cannula for pediatric anesthetic induction

Conditions: Oxygen Deficiency

Summary: endotracheal intubation in infants often involves more than one attempt, and oxygen desaturation is common. it is unclear whether nasal high-flow therapy, which extends the time to desaturation during elective intubation in infants receiving general anesthesia, can decrease the occurence of desaturation during intubation. the investigators tested the hypothesis that high-flow nasal oxygen cannulae would be effective in maintaining oxygen saturation during intubation than facemasks for pre-oxygenation. the investigators randomly allocated 132 patients undergoing elective surgery aged \<=12 months to pre-oxygenation using either high-flow nasal oxygen or facemask.


Eligibility criteria:
inclusion criteria: * infants undergoing general anesthesia with endotracheal intubation. exclusion criteria: * infants who diagnosed as cardiorespiratory problem preoperatively.